Novel Approaches to Target MECOM/EVI1 in AML

Novel Approaches to Target MECOM/EVI1 in Acute Myeloid Leukemia

This is an academic, no-profit, multicenter, biological, non-pharmacologic study aimed at characterizing genome, transcriptome and proteome of patients affected by AML with MECOM or atypical 3q26 rearrangements.

This is an academic, no-profit, multicenter, biological, non-pharmacologic study aimed at characterizing genome, transcriptome and proteome of patients affected by AML with MECOM or atypical 3q26 rearrangements. To this end, BM samples and formalin fixed/paraffin-embedded BM biopsies will be collected at enrolment, before and after treatment, at relapse.

Inclusion Criteria:

• AML with MECOM or atypical 3q26 rearrangements.
• Age ≥18.
• Signed written informed consent according to ICH/EU/GCP and national local laws.

Exclusion Criteria:

• None